- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04745702
Food Based Intervention Rich in Plant Components to Improve Metabolic Health in Prediabetics (FBIP) Study
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The worldwide prevalence of type 2 diabetes has increased by more than two-fold over the past three decades, with ~60% of diabetics in the world currently living in Asian countries. Type 2 diabetes occurs at a younger age and at lower body mass index (BMI < 22 kg/m2) in Asians as compared other ethnic groups. Among the various evidence based approaches to diabetes prevention, diet plays one of the most important roles. In particular, food based interventions are beginning to emerge as superior strategies in the prevention of type 2 diabetes compared to nutrient based approaches. It is important of course to align food based interventions to the cultural and region specific aspects of food choice and eating behavior if such lifestyle pattern is to be implemented in a given population. To this effect, the investigators will investigate the effects of a multiple food components in combination on metabolic health outcomes, within an Asian dietary context. This proposed study will be undertaken in prediabetics who are at greater life-time risk of developing type 2 diabetes than their normoglycemic counterparts.
Based on the current evidence, the investigators will design a food based intervention consisting of a diet rich in legumes, low GI starches (such as rice, noodles),healthier vegetable oil blends (such as rice bran, peanut, sesame seed and sunflower oils) as well as certain herbs and spices. As part of this study, each volunteer will be provided with 2 of their 3 meals per day, consisting of the above mentioned foods, for a period of 16 weeks. The control group will also be provided 2 meals per day, matched for the total calorie contents. The total calorie content of each provided meal will be approximately 500 kcal for males and 400 kcal for females. The difference in the calorie contents between the genders will be made up by using prepacked snacks. There will also be further differences in the snack types between the two intervention (treatment vs control) groups. While the treatment group will consist of healthier snacks such as seeds and wholemeal crackers, the control group snack ingredients will be made from refined flour biscuits etc. The remaining foods (free choice) during the day will be monitored regularly by the study dietitian to ensure a small calorie deficit that should lead to an approximately 5% weight loss in both intervention and control groups. Therefore, while it is expected that even the control group will achieve some metabolic health benefits during this 16 week dietary intervention (indirectly due to weight loss), the investigators anticipate that the treatment group will attain greater benefits as compared to the control group, due to the differences in their food constituents. The effects of dietary interventions on metabolic health will be assessed at every 4-8 week intervals. The primary outcome measures will include several markers of glucose homeostasis (including HbA1c, fasting glucose, fasting insulin and a 2-hr oral glucose tolerance test [OGTT]). The secondary outcomes will include blood lipid profile, fructosamine, adiponectin, markers of oxidative stress and chronic inflammation.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Singapore, Singapur, 117599
- Clinical Nutrition Research Centre
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Chinese Male or Female• Age between 45-75 years
- Body mass index 19.5-32.0 kg/m2
- Deemed to be prediabetic based on meeting any 1 of 3 following criteria:1. Fasting blood glucose >5.5 mmol/l and <7.0 mmol/l2. Oral glucose tolerance test (OGTT) level >/=7.8 mmol/l and </=11.0 mmol/l3. Haemoglobin A1c (HbA1c) level >/=5.7 and </=6.4%.
Exclusion criteria:
- Smoking
- Having allergies or intolerances to any common food ingredients including eggs, fish, milk, peanuts, and tree nuts, shellfish, soya, wheat, gluten, cereal, fruits, dairy products, meat, vegetable, sugar and sweetener, natural food colourings or flavourings, etc.
- Following special diets or having intentional dietary restrictions (e.g, vegetarians/vegans)
- Not willing to adhere to diet modification as in the study protocol
- Not willing to stop any strenuous activity during or within 24 hours of test days (for those actively participating in sports at the competitive and/or endurance levels)
- Having glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency)
- Having alcohol consumption on > 4 days per week with ≥ 6 alcoholic drinks per week
- Having sustained elevation of blood pressure (>160/95 mm Hg)
- Having previously undergone any gastrointestinal surgery or having history of gastrointestinal disorders
- Having a history of heart, liver, kidney, blood disorders (e.g., thalassemia) or thyroid dysfunctions
- Diabetic
- Having history of tuberculosis, HIV, Hepatitis B or Hepatitis C infections
- Having any prescription medication or any other alternative medicines or supplements which may interfere with study measurements in the in the opinion of the study investigators
- Having antibiotics or suffering from diarrhea within the last 3 months
- Having donated blood within 4 weeks of study participation
- Having poor veins or having history of severe vasovagal syncope (blackouts or fainting) from blood draws
- Having more than 5% weight loss or gain over the past 3 months
- For female volunteers: menstruation within past 12 months or being on hormone replacement therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Low-Calorie Control Group
The control group will receive for 2 calorie-restricted balanced meals per day, consisting of a portion of meat, a portion of vegetables, a portion of medium to high GI carbohydrates and prepared with refined corn oil.
The control meals will be devoid of any whole legumes and will contain minimal amounts of spices.
The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian.
Calorie restriction aims to reduce weight of participants by ~5%.
|
Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
|
|
Comparador activo: Low-Calorie Treatment Group
The treatment group will receive for 2 calorie-restricted (isocaloric with control group) meals per day containing 100 g cooked whole legumes (amounting to a total of 200 g cooked legumes, approximately 1 cup of cooked legumes)and/or certain meat analogues (textured vegetable [soy] proteins), and/or a portion of vegetables, low GI, wholegrain carbohydrates for their starch sources (rice/noodles/pasta), added spices (dried spice powder) at dietary and culinary acceptable doses and blended vegetable oil.
The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian.
Calorie restriction aims to reduce weight of participants by ~5%.
|
Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
HbA1c
Periodo de tiempo: 16 weeks
|
mmol/mol (%)
|
16 weeks
|
|
Fasting glucose
Periodo de tiempo: 16 weeks
|
mmol/L
|
16 weeks
|
|
Fasting insulin
Periodo de tiempo: 16 weeks
|
pmol/L
|
16 weeks
|
|
Oral Glucose Tolerance Test
Periodo de tiempo: 16 weeks
|
mmol/L
|
16 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proteína C-reactiva
Periodo de tiempo: 16 semanas (desde la primera hasta la última visita de medición), medido cada 8 semanas
|
miligramos por litro
|
16 semanas (desde la primera hasta la última visita de medición), medido cada 8 semanas
|
|
Blood Lipid Profile (HDL, LDL, Total Cholesterol, Triglyceride)
Periodo de tiempo: 16 weeks (from first to final measurement visits), measured every 4 weeks
|
mmol/L
|
16 weeks (from first to final measurement visits), measured every 4 weeks
|
|
Fructosamine
Periodo de tiempo: 16 weeks (from first to final measurement visits), measured every 4 weeks
|
µmol/L
|
16 weeks (from first to final measurement visits), measured every 4 weeks
|
|
Plasma Adiponectin
Periodo de tiempo: 16 weeks (from first to final measurement visits), measured every 4 weeks
|
μg/mL
|
16 weeks (from first to final measurement visits), measured every 4 weeks
|
|
Oxidised LDL
Periodo de tiempo: 16 weeks (from first to final measurement visits), measured every 4 weeks
|
ng/mL
|
16 weeks (from first to final measurement visits), measured every 4 weeks
|
|
IL-6 (interleukin 6)
Periodo de tiempo: 16 weeks (from first to final measurement visits), measured every 8 weeks
|
pg/mL
|
16 weeks (from first to final measurement visits), measured every 8 weeks
|
|
TNF (Tumor Necrosis Factor - alpha)
Periodo de tiempo: 16 weeks (from first to final measurement visits), measured every 8 weeks
|
pg/mL
|
16 weeks (from first to final measurement visits), measured every 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2019/00997
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .